Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT03188874
Recruiting Observational

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

NCT03188874 · tracked via the Priya Life Science Germany tracker
Sponsor
Technische Universität Dresden
Phase
Observational
Started
2010-09
Last updated
2026-04-21

Condition(s) studied

Acute Myeloid Leukemia (AML)

Study summary

This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia.

Investigator's sites: 60 sites in Germany.

Primary objectives:

* Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry.
* Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS)
* Documentation of treatment strategy

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia * Age ≥ 18 years. There is no upper age limit. * Signed written informed consent Exclusion Criteria: * there are no exclusion criteria

Primary outcome measure(s)

  • Epidemiological parameters — 10 years
    Epidemiological parameters
  • Relapse free survival (RFS) — 10 years
    Relapse free survival
  • Time to relapse (TTR), — 10 years
    Time to relapse (TTR),
  • Overall Survival (OS) — 10 years
    Overall Survival (OS)
  • cumulative incidence of relapse (CIR) — 10 years
    cumulative incidence of relapse (CIR)

Trial sites (60)

FacilityCityRegionStatus
Klinikum Mittelbaden Baden-Baden Baden-Wurttemberg Recruiting
Universtitätsklinikum Heidelberg Heidelberg Baden-Wurttemberg Recruiting
Klinikum Mannheim GmbH Mannheim Baden-Wurttemberg Recruiting
Diakonie-Klinikum Schwäbisch Hall Baden-Wurttemberg Recruiting
Kliniken Sindelfingen-Böblingen gGmbH Sindelfingen Baden-Wurttemberg Recruiting
Robert-Bosch-Krankenhaus GmbH Stuttgart Baden-Wurttemberg Recruiting
Rems-Murr-Klinikum Winnenden Winnenden Baden-Wurttemberg Recruiting
Klinikum Augsburg Augsburg Bavaria Recruiting
Sozialstiftung Bamberg Bamberg Bavaria Recruiting
Klinikum Bayreuth GmbH Bayreuth Bavaria Recruiting
MVZ Klinikum Coburg GmbH Coburg Bavaria Recruiting
ONKO Medeor Onkologische Zentren Donauwörth Bavaria Recruiting
Universitätsklinikum Erlangen Erlangen Bavaria Recruiting
Klinikum Nürnberg Nuremberg Bavaria Recruiting
Universitätsklinikum Würzburg Würzburg Bavaria Recruiting
Carl-Thiem-Klinikum Cottbus gGmbH Cottbus Brandenburg Recruiting
Klinikum Frankfurt (Oder) GmbH Frankfurt (Oder) Brandenburg Recruiting
Universitätsklinikum Frankfurt Frankfurt am Main Hesse Recruiting
Klinikum Fulda / MVZ Osthessen GmbH Fulda Hesse Recruiting
Universitätsklinikum Gießen und Marburg Marburg Hesse Recruiting
Dr. Horst Schmidt Kliniken GmbH Wiesbaden Hesse Recruiting
St. Bernward Krankenhaus Hildesheim Hildesheim Lower Saxony Recruiting
Agaplesion Diakonieklinikum Rotenburg Rotenburg (Wümme) Lower Saxony Recruiting
Klinikum Wolfsburg Wolfsburg Lower Saxony Recruiting
Diakonie Klinikum Dietrich Bonhoeffer Neubrandenburg Mecklenburg-Vorpommern Recruiting
Klinikum Südstadt Rostock Rostock Mecklenburg-Vorpommern Recruiting
HELIOS Klinikum Schwerin Schwerin Mecklenburg-Vorpommern Recruiting
Marien Kliniken, St. Marien-Krankenhaus Siegen Nordhein-Westfalen Recruiting
Universitätsklinikum Aachen Aachen North Rhine-Westphalia Recruiting
Städt. Kliniken Bielefeld gem. GmbH - Klinikum Mitte Bielefeld North Rhine-Westphalia Recruiting
Augusta Kranken Anstalt Bochum Bochum North Rhine-Westphalia Recruiting
Klinikum der Universität zu Köln Cologne North Rhine-Westphalia Recruiting
Helios Klinikum Duisburg Duisburg North Rhine-Westphalia Recruiting
Helios Klinikum Duisburg Duisburg North Rhine-Westphalia Recruiting
Krankenhaus Düren gGmbH Düren North Rhine-Westphalia Recruiting
Universitätsklinikum Düsseldorf Düsseldorf North Rhine-Westphalia Recruiting
Alfried Krupp Krankenhaus Rüttenscheid Essen North Rhine-Westphalia Recruiting
Universitätsklinikum Essen Essen North Rhine-Westphalia Recruiting
Klinikum Gütersloh Gütersloh North Rhine-Westphalia Recruiting
St. Barbara-Klinik Hamm GmbH Hamm North Rhine-Westphalia Recruiting

+ 20 more sites — see the full list on the official registry below.

More Technische Universität Dresden trials in Germany

Machine Learning-based Surgical Guidance System for Robot-assisted Rectal Surgery Recruiting
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation Recruiting
Neurocognitive Function After Proton Therapy in Children and Adolescents Recruiting
Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases Recruiting
Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety Recruiting

Other trials for the same condition

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML Recruiting
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations Active, not recruiting
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy Active, not recruiting
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project Recruiting
Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03188874 on ClinicalTrials.gov ↗ ← All trials in Germany